Related Experiment Video
Updated: Dec 19, 2025
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
Published on: June 5, 2020
Dural Marginal Zone Lymphoma in a Patient With a Hepatitis C Virus Infection
Matthew T Villaume1, Dilan Patel2, Christine Lopez1
1Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Abstract:
Primary dural marginal zone lymphomas (MZLs) are exceptionally rare, with fewer than 100 cases reported to date. While the association between hepatitis C virus (HCV) infection and lymphoma is well established, it is unclear if this association extends to all anatomic sites. Here we report a case of dural MZL in a 61-year-old woman with an HCV infection. To our knowledge, this is the first report of a dural MZL associated with an HCV infection in an immunocompetent patient and was successfully treated with radiotherapy and rituximab. As such, future cases of primary MZL found in the dura should prompt consideration of co-infection with microbials such as HCV and upfront treatment with anti-virals should be considered.
Insights
Primary dural marginal zone lymphoma (MZL) is rare. This case report details a dural MZL associated with hepatitis C virus (HCV) infection in an immunocompetent patient, successfully treated with radiotherapy and rituximab.
Area of Science:
- Hematology
- Oncology
- Neurology
Background:
- Primary dural marginal zone lymphomas (MZLs) are exceedingly rare neoplasms, with limited documented cases.
- The link between hepatitis C virus (HCV) infection and lymphoma is recognized, but its association with specific anatomical sites like the dura mater remains unclear.
Observation:
- A case of primary dural MZL is presented in a 61-year-old immunocompetent female patient with a known HCV infection.
- This represents the first reported instance of a dural MZL linked to HCV infection in an immunocompetent individual.
Findings:
- The dural MZL in this patient demonstrated a positive association with HCV infection.
- Successful treatment was achieved using a combination of radiotherapy and rituximab.
Implications:
- The findings suggest that primary MZL of the dura should prompt investigation for co-infections, such as HCV.
- Early consideration of antiviral therapy alongside standard treatments like radiotherapy and rituximab may be beneficial for future cases.
